12/22
11:03 am
sngx
SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]
Low
Report
SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]
12/18
08:12 am
sngx
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]
Medium
Report
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]
12/18
07:30 am
sngx
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Medium
Report
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
12/17
07:41 am
sngx
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis [Yahoo! Finance]
High
Report
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis [Yahoo! Finance]
12/17
07:30 am
sngx
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
High
Report
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
12/5
08:44 am
sngx
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad [Yahoo! Finance]
Medium
Report
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad [Yahoo! Finance]
12/5
08:30 am
sngx
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
Low
Report
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
12/3
08:30 am
sngx
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Low
Report
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
11/19
08:05 am
sngx
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Medium
Report
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma [Yahoo! Finance]
11/19
07:30 am
sngx
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Low
Report
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
11/9
05:23 am
sngx
Soligenix GAAP EPS of -$0.58 beats by $0.05 [Seeking Alpha]
Low
Report
Soligenix GAAP EPS of -$0.58 beats by $0.05 [Seeking Alpha]
11/7
07:57 am
sngx
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results [Yahoo! Finance]
11/7
07:30 am
sngx
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Medium
Report
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
10/14
07:51 am
sngx
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Low
Report
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
10/14
07:30 am
sngx
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Medium
Report
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
10/7
07:30 am
sngx
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Medium
Report
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
9/30
07:55 am
sngx
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Low
Report
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
9/30
07:30 am
sngx
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Low
Report
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
9/29
04:05 pm
sngx
Soligenix Announces Closing of $7.5 Million Public Offering
Low
Report
Soligenix Announces Closing of $7.5 Million Public Offering
9/26
06:58 am
sngx
Soligenix Announces Pricing of $7.5 Million Public Offering [Yahoo! Finance]
Medium
Report
Soligenix Announces Pricing of $7.5 Million Public Offering [Yahoo! Finance]
9/26
06:33 am
sngx
Soligenix Announces Pricing of $7.5 Million Public Offering
High
Report
Soligenix Announces Pricing of $7.5 Million Public Offering
9/23
07:30 am
sngx
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
High
Report
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor